{"title":"[J-CATIA研究(日本阿尔茨海默病抗精神病药物治疗联盟)建议]。","authors":"Heii Arai","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The mortality risk of long-term and new antipsychotic drug use in Alzheimer's disease (AD) patients in Japan was studied to determine improved treatment protocols. One of the main findings was that newly prescribed users showed increased mortality. Therefore, the new use of antipsychotic drugs represents a distinct mortality risk, while those on long-term anti- psychotic therapy are suggested to be relatively safe.</p>","PeriodicalId":21638,"journal":{"name":"Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica","volume":"118 11","pages":"845-848"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Suggestions Obtained from the J-CATIA Study (Japan Consortium for Antipsychotics Treatment in Alzheimer's Disease)].\",\"authors\":\"Heii Arai\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The mortality risk of long-term and new antipsychotic drug use in Alzheimer's disease (AD) patients in Japan was studied to determine improved treatment protocols. One of the main findings was that newly prescribed users showed increased mortality. Therefore, the new use of antipsychotic drugs represents a distinct mortality risk, while those on long-term anti- psychotic therapy are suggested to be relatively safe.</p>\",\"PeriodicalId\":21638,\"journal\":{\"name\":\"Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica\",\"volume\":\"118 11\",\"pages\":\"845-848\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[Suggestions Obtained from the J-CATIA Study (Japan Consortium for Antipsychotics Treatment in Alzheimer's Disease)].
The mortality risk of long-term and new antipsychotic drug use in Alzheimer's disease (AD) patients in Japan was studied to determine improved treatment protocols. One of the main findings was that newly prescribed users showed increased mortality. Therefore, the new use of antipsychotic drugs represents a distinct mortality risk, while those on long-term anti- psychotic therapy are suggested to be relatively safe.